Iron Infusions Narrowly Miss the Mark for Clinical Benefit in Heart Failure
AMSTERDAM — Ferric carboxymaltose (FCM) did not go so far as to improve hard outcomes in people with heart failure with reduced ejection fraction (HFrEF) and iron deficiency in the well-powered HEART-FID trial, and it is questionable whether it is headed in that direction based on the totality of the evidence. Between study participants randomized […]